OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE Executive Office of the President Washington, D.C. 20508 For Immediate Release April 30, 1999 Contact: Jay Ziegler, Helaine Klasky, Amy Stilwell, (202) 395-3230 USTR ANNOUNCES RESULTS OF SPECIAL 301 ANNUAL REVIEW United States… Continue Reading
Public and Private Sector Funded Research for Fabry’s Disease KEI Research Note 2010:2 23 July 2010 Introduction Fabry’s disease is a rare genetic multisystemic disorder associated with progressive lipid accumulation and cell damage, leading to a variety of aliments, including… Continue Reading
See Kazakhstan Timelines for: 1990-2000 , 2001, 2002, 2003 , 2004, 2005, 2006, 2007. 2001 January. Ted Turner founds the Nuclear Threat Initiative (NTI), co-chaired by Turner and former Senator Sam Nunn. 2001 January 25. Michael Dobbs story in Washington… Continue Reading
Kazakhstan Time-Line 1989- 2000 1949 The Soviet Union conducts a successful atomic test in Kazakhstan, and the nuclear arms race between the Soviet Union and the U.S. begins. 1949. The Ulba Metallurgy Plant is established, and is referred to ask… Continue Reading
2000 May 20, 2000 – WHO passes WHA 53.17, which calls for research, prevention, collaboration, and capacity building to prevent and control noncommunicable diseases 2002 April 13, 2002 –The Salt Institute and other industry lobbying groups release their first comments… Continue Reading
Other KEI timelines. KEI web page on WIPO broadcasting treaty negotiation. 1961 Concluded at Rome on 26 October 1961 in Rome, Rome Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organizations 1997 28-30 April 1997, World Symposium… Continue Reading
PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading
1994 1994: Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States, May 12. A discussion of how R&D mandates can ensure innovation does not suffer when prices lowering policies are embraced. 1996 1996: Comments… Continue Reading
Signatures to the petition to President Obama, regarding transparency of ACTA Back to the petition US signatories Knowledge Ecology International David Bollier, Onthecommons.org U.S. Public Interest Research Group Essential Action Health Action International (HAI) Global Public Citizen Ellen Miller, Sunlight… Continue Reading
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading